Lanean...
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to...
Gorde:
| Argitaratua izan da: | Psoriasis (Auckl) |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717840/ https://ncbi.nlm.nih.gov/pubmed/31696051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S161453 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|